Complement C3 and C4 tests measure two abundant proteins in the complement system, an immune network that helps antibodies clear microbes and damaged cells. In a vasculitis evaluation, the results do not prove or exclude blood vessel inflammation. Instead, the pattern can suggest whether immune complexes are consuming complement, whether the alternative pathway may be unusually active, or whether another explanation such as infection, liver disease, protein loss, or an inherited deficiency deserves attention. Low C4 is especially useful when cryoglobulinemic vasculitis is suspected, while low C3 and C4 together can support active lupus or another immune-complex process. Many serious forms of vasculitis, including most ANCA-associated vasculitis, occur with normal C3 and C4. Interpretation therefore depends on symptoms, urine findings, kidney function, antibody tests, infection studies, trends over time, and sometimes a tissue biopsy. This guide explains what common C3/C4 combinations mean and what clinicians usually check next.
- C3 and C4 are protein concentrations, not direct measurements of total complement function.
- Low C4, particularly with normal or mildly reduced C3, is a classic clue to mixed cryoglobulinemia.
- Low C3 and C4 together often point toward classical-pathway consumption from immune complexes.
- Normal levels do not rule out ANCA-associated, anti-GBM, or skin-limited vasculitis.
- A single abnormal result should be interpreted with the laboratory range, clinical picture, and repeat testing when appropriate.
Table of Contents
- What C3 and C4 Measure
- How to Read C3/C4 Patterns
- Low C4 and Cryoglobulinemic Vasculitis
- Low C3 and C4 in Immune-Complex Disease
- Normal Complement and ANCA Vasculitis
- Other Causes, Testing Limits, and Trends
- Follow-Up Tests and When Results Are Urgent
What C3 and C4 Measure
Complement is a coordinated group of blood proteins that can be activated through the classical, lectin, or alternative pathway. These routes converge on reactions that label targets for removal, recruit inflammatory cells, and form membrane-attacking complexes. C3 sits near the center of all three pathways. C4 is used mainly by the classical and lectin pathways. That difference helps explain why their combined pattern can offer clues about which part of the system is active.
A routine C3 or C4 test usually measures the amount of each protein in serum, commonly by immunoturbidimetry or a related laboratory method. It does not show how efficiently the full cascade works. A person can have a concentration within range while a pathway is being activated, and a low concentration may reflect consumption, reduced production, loss from the body, or an inherited baseline rather than active vasculitis.
This distinction is why C3 and C4 are often paired with a functional assay. A CH50 test in a vasculitis evaluation assesses the ability of the classical pathway and terminal complement components to complete a reaction. An AH50 or AP50 assay evaluates the alternative pathway. Concentration and function answer different questions, so one does not replace the other.
C3 and C4 are also acute-phase proteins. Inflammation can increase production at the same time that immune activation consumes them. A result that remains technically “normal” may therefore hide a meaningful fall from a patient’s usual level. Conversely, a modestly high value is generally nonspecific and is not evidence that the complement system is “too strong.”
Reference intervals vary by laboratory, method, age, sex, and population. Results should always be read against the range printed on the report. Common adult ranges are roughly 0.8–1.9 g/L for C3 and 0.1–0.6 g/L for C4, but these are not universal diagnostic cutoffs. The direction and persistence of change are usually more informative than a small isolated deviation.
How to Read C3/C4 Patterns
The most useful first step is to interpret C3 and C4 together rather than labeling either result simply “low” or “normal.” The table below summarizes common patterns, but it cannot identify a diagnosis by itself.
| Pattern | What it may suggest | Examples to consider |
|---|---|---|
| Low C4 with normal or mildly low C3 | Predominantly classical-pathway activation or a low constitutional C4 level | Mixed cryoglobulinemia, some lupus activity, C1-inhibitor deficiency, inherited low C4 copy number |
| Low C3 and low C4 | Broad classical-pathway consumption, often from immune complexes | Active lupus, immune-complex glomerulonephritis, infective endocarditis, severe infection, cryoglobulinemia |
| Low C3 with normal C4 | Alternative-pathway activation or dysregulation | Post-infectious glomerulonephritis, C3 glomerulopathy, sepsis, factor H or factor I abnormalities |
| Normal C3 and C4 | No major circulating depletion detected | Common in ANCA-associated vasculitis, anti-GBM disease, many skin-limited vasculitides, or inactive immune-complex disease |
| High C3 and/or C4 | Nonspecific increased production | Acute or chronic inflammation, infection, metabolic inflammation, recovery from prior consumption |
A pattern narrows possibilities; it does not establish cause. Low C3 and C4 in a person with blood and protein in the urine raises a different concern from the same values in someone with advanced liver disease and no inflammatory symptoms. Likewise, low C4 accompanied by palpable purpura, neuropathy, rheumatoid-factor positivity, and hepatitis C exposure is more suggestive of mixed cryoglobulinemia than low C4 found incidentally during a wellness evaluation.
Timing matters. Complement may fall during active immune-complex disease and rise as the process improves. However, normalization does not guarantee that all organ inflammation has resolved, and persistently low values do not always mean treatment failure. Some people have genetically lower levels, while chronic liver disease or ongoing protein loss can keep concentrations reduced.
Clinicians therefore compare the complement pattern with the pretest probability created by the history and examination. They also review the absolute values, prior results, medications, specimen quality, kidney and liver tests, inflammatory markers, immunoglobulins, and disease-specific studies. The C3 result and C4 result are most useful as parts of that larger picture.
Low C4 and Cryoglobulinemic Vasculitis
A disproportionately low C4 is one of the most recognizable laboratory clues to mixed cryoglobulinemia. In types II and III cryoglobulinemia, immunoglobulins form circulating immune complexes that can activate the classical complement pathway. C4 may be markedly depleted while C3 remains normal or falls less dramatically. This pattern is supportive, not diagnostic: the person still needs appropriate cryoglobulin testing and assessment for organ involvement and an underlying cause.
Symptoms that make low C4 more meaningful include recurrent palpable purpura on the legs, joint pain, fatigue, burning or numb sensations in the feet or hands, weakness from peripheral nerve injury, Raynaud-type color changes, skin ulcers, and kidney abnormalities. Urinalysis may show blood, protein, or cellular casts, and creatinine may rise if cryoglobulinemic glomerulonephritis is present. Rheumatoid factor is often positive because the IgM component in type II disease commonly has rheumatoid-factor activity.
The cryoglobulin test requires unusually careful collection and handling. Blood must be kept warm until serum is separated because premature cooling can remove cryoglobulins from the sample and produce a false-negative result. A negative test does not fully dismiss the diagnosis when the clinical pattern and low C4 are compelling; repeat collection through an experienced laboratory may be appropriate.
Hepatitis C remains an important cause worldwide, even though effective antiviral therapy has reduced its frequency in many settings. Other associations include Sjögren disease, systemic lupus erythematosus, hepatitis B, HIV, chronic infections, and B-cell or plasma-cell disorders. Testing often includes hepatitis serology and viral load when indicated, serum protein electrophoresis with immunofixation, quantitative immunoglobulins, free light chains, and evaluation for autoimmune disease.
Low C4 is not specific to cryoglobulinemia. It can occur in lupus, hereditary or acquired C1-inhibitor deficiency, autoimmune hemolytic anemia, and some infections. A person with recurrent nonitchy swelling of the face, lips, limbs, abdomen, or airway but no hives may need C1-inhibitor testing rather than a vasculitis workup. Clinical details determine which explanation rises to the top.
Low C3 and C4 in Immune-Complex Disease
When both C3 and C4 are low, clinicians often consider substantial classical-pathway activation by immune complexes. Systemic lupus erythematosus is a leading example. Antibody–antigen complexes can activate complement in the circulation and tissues, and falling C3 and C4 may accompany active disease, especially lupus nephritis. The finding becomes more concerning when paired with rising anti-double-stranded DNA antibodies, new proteinuria or hematuria, cellular casts, edema, high blood pressure, or declining kidney function.
Complement trends are useful in established lupus, but they are not an independent disease-activity score. Some flares occur without low complement, and some patients remain chronically low while clinically stable. A change from the person’s baseline, interpreted alongside symptoms and urine findings, is usually more valuable than comparing one result with a population reference interval.
Other immune-complex conditions can produce a similar pattern. Infection-related glomerulonephritis may follow or occur during bacterial infection. Infective endocarditis can cause fever, constitutional symptoms, a heart murmur, embolic findings, kidney inflammation, low complement, and sometimes positive autoantibodies that confuse the picture. Starting immunosuppression before excluding an occult infection can be dangerous, so blood cultures, echocardiography, and directed infection testing may be essential when the history supports them.
Low C3 with relatively preserved C4 shifts attention toward the alternative pathway. This can occur in post-infectious glomerulonephritis, C3 glomerulopathy, and acquired or inherited abnormalities of complement regulation. Persistent low C3 after an expected infection-related illness has resolved may prompt specialist testing for C3 nephritic factor, factor H or factor I abnormalities, complement autoantibodies, or genetic variants. Kidney biopsy is often required to distinguish immune-complex glomerulonephritis from C3-dominant disease.
Hypocomplementemic urticarial vasculitis is another relevant entity. It causes recurrent urticarial lesions that typically last longer than 24 hours, may burn or hurt rather than itch, and can leave bruising or pigmentation. Low complement—often including C1q—and anti-C1q antibodies can support the diagnosis, while lung, kidney, eye, joint, and gastrointestinal involvement affect severity. This differs from ordinary hives, which usually fade within hours without residual discoloration.
The broad lesson is that low complement points toward a mechanism, not a single disease. The clinician still has to identify the source of immune complexes, determine which organs are affected, and decide whether biopsy is needed.
Normal Complement and ANCA Vasculitis
Normal C3 and C4 do not rule out vasculitis. Most patients with granulomatosis with polyangiitis, microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis have circulating C3 and C4 concentrations within their laboratory’s reference interval. These disorders are classically described as pauci-immune because tissue biopsy shows little or no immunoglobulin and complement deposition compared with immune-complex disease.
That description does not mean complement is biologically irrelevant. Research shows that alternative-pathway activation, especially signaling through C5a, contributes to neutrophil activation and tissue injury in ANCA-associated vasculitis. The pathway may be active locally or through short-lived fragments without lowering total circulating C3 or C4 enough to cross the laboratory cutoff. Therefore, normal concentration tests cannot be used as evidence that ANCA vasculitis is mild or absent.
When ANCA-associated vasculitis is suspected, the more decisive information comes from the clinical syndrome and organ testing. Warning patterns include rapidly worsening kidney function, blood and protein in urine, coughing blood, new lung infiltrates, chronic destructive sinus disease, hearing changes, mononeuritis multiplex, palpable purpura, or unexplained systemic inflammation. Testing may include MPO-ANCA and PR3-ANCA, urinalysis with microscopy, urine protein quantification, creatinine, blood counts, chest imaging, and biopsy of an affected organ.
Low complement in an ANCA-positive patient deserves special attention because it may suggest an overlapping or alternative process. Infection—particularly endocarditis—can generate ANCA positivity, low complement, and glomerulonephritis. Lupus, cryoglobulinemia, immune-complex glomerulonephritis, and rare overlap syndromes can also produce mixed findings. A positive ANCA test should never override evidence for infection or immune-complex disease.
Anti-GBM disease and many cases of isolated cutaneous small-vessel vasculitis may also occur with normal C3 and C4. Diagnosis in those settings rests on disease-specific antibodies, skin or kidney biopsy, urine abnormalities, pulmonary findings, medication and infection history, and the overall clinical course.
Other Causes, Testing Limits, and Trends
Low complement does not always represent active immune consumption. The liver produces most complement proteins, so advanced liver dysfunction can reduce concentrations. Severe malnutrition may impair production. Nephrotic-range protein loss, protein-losing intestinal disease, extensive burns, or other states of protein loss can lower levels. These explanations become more plausible when albumin, liver enzymes, coagulation studies, urine protein, or nutritional assessment are abnormal.
Inherited complement deficiencies are uncommon but important. Deficiencies of early classical-pathway components can predispose to lupus-like autoimmunity, while deficiencies affecting C3 or the terminal pathway increase susceptibility to serious or recurrent bacterial infections. A lifelong history of unusual infections, affected relatives, or repeatedly abnormal complement results during otherwise healthy periods may lead to CH50, AH50, individual component measurements, and immunology or genetic evaluation.
A persistently isolated low C4 can also reflect inherited variation in C4 gene copy number. Some healthy people naturally run below the standard range. This possibility is considered only after symptoms, prior values, family history, and functional testing are reviewed; it should not be assumed from one result.
Preanalytic and analytic factors matter. Complement proteins can continue to activate after blood is drawn if a specimen is delayed, mishandled, or stored incorrectly, although routine C3/C4 concentration assays are generally less fragile than functional CH50 testing. Laboratories use different methods and reference intervals, so trends are best followed through the same laboratory when practical. Mild results near a cutoff may change classification simply because of method variation.
High C3 or C4 is usually an acute-phase response. It can accompany infection, obesity-related inflammation, diabetes, inflammatory disorders, or recovery after a period of consumption. High values do not diagnose vasculitis and usually do not require a complement-specific workup unless other findings indicate one.
For monitoring, clinicians look for concordance. In immune-complex disease, improving symptoms, stabilizing kidney function, cleaner urine sediment, falling proteinuria, and recovering complement are reassuring when they move together. If complement normalizes but kidney findings worsen, the organ data take priority. If values stay low despite clinical improvement, baseline deficiency, ongoing production problems, or another persistent driver may need consideration.
Follow-Up Tests and When Results Are Urgent
The next test depends on the pattern and the organ system involved. A common evaluation for suspected immune-complex vasculitis or glomerulonephritis includes urinalysis with microscopy, urine protein-to-creatinine or albumin-to-creatinine ratio, serum creatinine and estimated glomerular filtration rate, complete blood count, liver tests, ESR or CRP, antinuclear antibodies, anti-double-stranded DNA antibodies, and immunoglobulin studies. The broader vasculitis blood test panel may add MPO-ANCA, PR3-ANCA, hepatitis testing, and other targeted markers.
For low C4 with purpura, neuropathy, or kidney findings, clinicians commonly order cryoglobulins, rheumatoid factor, hepatitis C antibody with confirmatory RNA testing when appropriate, hepatitis B tests, HIV testing based on risk, serum protein electrophoresis, immunofixation, and free light chains. Because cryoglobulin collection is technically demanding, the laboratory should provide handling instructions before the blood draw.
For low C3 with normal C4 and persistent glomerulonephritis, nephrology may consider CH50 and AH50, C3 nephritic factor, factor H and factor I studies, soluble complement activation products, monoclonal protein testing, and genetic analysis. These specialized studies are not screening tests for everyone with a mildly low C3.
A biopsy may be the fastest way to separate competing diagnoses. Kidney biopsy can distinguish pauci-immune crescentic glomerulonephritis, immune-complex disease, anti-GBM disease, and C3-dominant patterns. Skin biopsy with direct immunofluorescence can help identify leukocytoclastic vasculitis and immune deposits when a fresh lesion is sampled. Complement results guide the differential, but tissue can define the injury mechanism more directly.
Seek urgent medical assessment for coughing blood, shortness of breath, rapidly decreasing urine output, dark or visibly bloody urine with swelling, a fast rise in creatinine, new severe weakness or foot drop, painful skin necrosis, confusion, chest pain, or signs of sepsis. These features may indicate pulmonary hemorrhage, rapidly progressive glomerulonephritis, nerve ischemia, tissue-threatening vasculitis, or infection. Treatment decisions should not wait for every send-out complement test when organ function is deteriorating.
For a nonurgent isolated abnormality, the usual approach is calmer: confirm the result, compare it with prior levels, review the laboratory range and medications, and repeat testing if the clinical context supports it. C3 and C4 are valuable clues, but their meaning comes from the pattern they form with symptoms, organ tests, disease-specific antibodies, and—when needed—biopsy.
References
- Complement Blood Test: MedlinePlus Medical Test. 2024.
- Complement C3 and C4. 2026. Laboratory test guide.
- The complement system and human autoimmune diseases. 2023. Review.
- Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. 2022. Review.
- Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. 2023. Review.
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. 2024. Guideline.
Disclaimer
This article is for general educational purposes and does not diagnose or treat any condition. Complement results must be interpreted by a qualified clinician alongside symptoms, examination findings, other laboratory tests, imaging, and biopsy results when indicated. Seek urgent care for breathing difficulty, coughing blood, rapidly worsening kidney symptoms, severe neurologic changes, or painful skin discoloration and tissue loss.
